Grit Biotechnology Named to 'China's Future Unicorns TOP100 2026' and Files IPO Prospectus

Recently, at the 10th Everything Growth Conference, the China Investment Development Promotion Association, in collaboration with the Micro-Chains Think Tank, officially released the "Top 100 List of China's Future Unicorns 2026." Grit Biotechnology successfully made it to the list and ranked among the "potential stocks" in China’s future industries, thanks to its continuous innovation capabilities and high growth potential in the biopharmaceutical field.

This list focuses on the direction of China's future industrial development, covering frontier areas such as artificial intelligence and embodied intelligence, advanced manufacturing and future energy, biomanufacturing, aerospace and marine technologies, quantum science and technology, brain-computer interfaces, etc. It systematically selects a group of enterprise representatives with disruptive technological innovation capabilities and high growth potential, aiming to depict China's future industrial landscape with a forward-looking perspective.

In the "Biomanufacturing" section, Grail Bio was selected alongside several innovative biotech companies, showcasing the company's technical strength and industrialization potential in the field of innovative therapies. As an innovative enterprise focusing on next-generation cell therapy and in vivo immune reprogramming technology, Grail Bio always adheres to clinical value as its orientation, continuously advancing the R&D and transformation of cutting-edge technologies such as in vivo CAR-T, committed to breaking through the bottleneck of solid tumor treatment and promoting the paradigm shift of cell therapy from "ex vivo manufacturing" to "in vivo generation."

Currently, the future industry represented by biomanufacturing has become a key layout direction in China's "15th Five-Year Plan" and is also a core track in global technological competition. This selection not only recognizes Grail Biotechnology's innovation capabilities but also reflects the high expectations of the industry and capital markets regarding the company’s long-term development potential.

Looking ahead, Grail Bio will continue to deepen its expertise in the cell and gene therapy field, enhance the layout of its diversified technology platforms, accelerate the clinical progress and global expansion of its core pipelines, and continuously explore more accessible and groundbreaking treatment solutions to create greater value for patients. At the same time, the company will actively integrate into China's future industrial development landscape, driving the growth of new quality productive forces through continuous innovation, and contributing to China's biopharmaceutical industry advancing to the global forefront.

AboutGravel Biotech

Grail Biotechnology, founded in 2019, is an innovation-driven biopharmaceutical company in the late clinical stage.，Focused on pioneering the next generation of immunotherapies for cancer and autoimmune disease patients worldwide. With deep insights into the field of immunotherapy, cutting-edge R&D and technology platforms, and world-class manufacturing capabilities, Gracell Biotechnologies has established multiple self-developed technology platforms in China and the United States, along with a diversified pipeline comprising several candidate products to address significant unmet clinical needs. The company’s self-developed GT101 injection is China’s first TIL drug approved for registrational clinical trials and is currently in a pivotal Phase II clinical trial. The self-developed GT201 injection, the world’s first TIL product incorporating a membrane-bound IL-15 complex, has completed dual IND filings in China and the U.S. and has been approved to enter Phase I clinical trials. Additionally, the company has a highly innovative dual-gene knockout autologous TIL therapy product, an mRNA vaccine targeting tumor neoantigens, the world’s first off-the-shelf CAR-iNKT cell therapy product derived from stem cells, and next-generation in vivo CAR-T therapies, forming a product portfolio of pan-solid tumor TIL drugs and off-the-shelf cell therapies.